October 07, (THEWILL) – The first new sickle-cell treatment in 20 years has shown the potential to reduce sufferers’ crisis by 50 percent in a year and holds the promise of keeping thousands of people out of hospital over the next three years, health authorities in England have said.
Sickle-cell disease is incurable.
And the National Institute for Health and Care Excellence said the hope of reducing health inequalities for Black people, who are predominantly affected and often have poorer health to start with, made the drug worth recommending.
It called it “an innovative treatment.”
The drug, Crizanlizumab, made by Novartis, is injected into the vein and can be taken on its own or alongside standard treatment and regular blood transfusions.
In a trial, patients taking the Crizanlizumab had a sickle-cell crisis 1.6 times a year on average, compared with nearly three times a year normally.
These painful episodes, which can require hospital treatment and lead to other health complications, are caused by sickle-shaped red blood cells blocking the small blood vessels .
Because the trial was small and lasted only a year, it remains unknown how long the benefits last for – and that makes it difficult to judge how cost-effective Crizanlizumab is.
Nevertheless, NICE, which recommends treatments in England and Wales, is recommending its use for over-16s, albeit under a special arrangement rather than routinely, on the NHS.
Additional data on the treatment will be collected through clinical trials.
The charity Sickle Cell Society said the new treatment brought “new hope” for people living with the world’s most common genetic blood condition.
NHS chief executive Amanda Pritchard said: “The moment that a new drug comes that is approved to be used, our job is to make sure that we can do a deal to ensure it’s affordable and get it out as quickly as possible.”
Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation, at NICE, said: “Treatment for sickle-cell disease has been limited for years and there has been a lack of treatments for patients whose lives are affected by the condition.
“Crizanlizumab… has shown the potential to improve hundreds of lives and we are delighted to be able to recommend it as the first new treatment for sickle cell disease in two decades.”
Sickle Cell is inherited from both parents, who pass on a particular gene, although it is possible to carry the gene without having the disease.
Children with sickle cell are at greater risk of stroke.
Other symptoms can include serious infections, anaemia and tiredness
About the Author
